Atea Pharmaceuticals (AVIR) 10-Q2023 Q1 Quarterly report

Filed: 8 May 23, 4:41pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: AbbVie, antidilutive, assimilated, augment, barrier, bundled, climate, collateralize, conferred, constant, constantly, COVID, deposit, depository, differentiated, diminution, distancing, driven, enriching, environment, Epclusa, ESG, evading, explore, expressly, fault, FDIC, fit, formation, GS, herd, hesitancy, host, indefinite, inflection, Intelligence, intravenously, intrinsic, Jiangsu, jointly, Junshi, letter, lingering, living, macroeconomic, Mavyret, maximize, metabolite, ministerial, mount, multicenter, nucleoside, nucleotityltransferase, obeldesivir, parallel, payer, PHE, precipitation, premarket, QD, resistance, resumption, rollout, SE, Shinogi, Silicon, Simcere, South, stakeholder, subset, substance, SVR, SyneuRx, temperature, timeline, uneven, unrecognized, Valley, virulence, wearing, week, weekly, whichever, Xocova

Removed: Abbreviated, account, acid, alleviation, analog, appointment, arrange, assessed, assumed, attenuated, avoided, batch, bear, began, biology, biometric, breakthrough, built, cancelation, chemistry, collecting, complied, comprised, crystallized, dated, deal, deep, Delta, DENV, destination, devoting, elongation, entirety, evaluable, evidenced, executed, fever, fourth, furnish, governance, guanosine, harder, healthy, Iceland, infected, insufficiency, interactive, Kingdom, lab, leased, leasehold, left, Leveraging, Liechtenstein, listing, mandatory, manifestation, medium, methodology, migrated, minimize, mission, modification, necessitated, NiRAN, nonstructural, Norway, objective, occupy, occurring, older, orally, orderly, partnership, platform, precautionary, predecessor, prevalent, PRI, principle, prioritized, protein, purine, quota, ranging, RdRp, realization, reclassified, reformed, regulated, relaxed, remdesivir, remote, replacing, represented, respiratory, ribonucleic, safest, scenario, secured, September, showed, showing, situation, small, specificity, spread, strain, suggest, suggested, Summary, Summer, syncytial, tariff, temporarily, titled, tolerated, transferred, transmissibility, treasury, unadjusted, underlying, unilaterally, upheld, vaccinated, variable, variant, virology, Wall, wind

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AVIR transcripts

AVIR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Atea Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 8, 2023	By:	/s/ Andrea Corcoran
		Andrea Corcoran
		Chief Financial Officer, Executive Vice President, Legal, and Secretary (principal financial officer)